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literature demonstrate that the outcome can also be influenced by the insulin
regimen used by the hospital. Objective of this study is the Budget Impact Analysis
(BIA) of the hospital use of aspart insulin with respect to other rapid insulin alter-
natives available on the market. METHODS: All the hospitalizations with evidence
of hyperglycaemia in one year in Italy were considered. Four alternatives were
evaluated: 1) aspart insulin; 2) lispro insulin; 3) glulisine insulin; 4) human insulin.
Administration of insulin regimen (basal rapid), length of hospital stay and inci-
dence of hypoglycaemic events were simulated. The rates of hypoglycaemic events
with rapid insulin alternatives, and the prolongation of hospital stay caused by
such an event were derived from international literature. Only differential costs
among alternatives were accounted for, i.e. purchase and administration of rapid
insulin and management of hypoglycaemic events. Epidemiologic and healthcare
resource consumption data derived from Italian published sources. Current prices
and tariffs were applied in the perspective of the hospital. RESULTS: A total of 7.7
million hospitalizations of adult patients in one year were considered, of which
23.6% (1.8 million) with evidence of hyperglycaemia. Total costs with the aspart
insulin resulted: €7.8 million for insulin, €7.4 million for administration and €507.0
million for hypoglycaemic events management (total: €522.2 million). Total costs
with the other rapid insulin alternatives were higher (range: 4% to 37.2%).
CONCLUSIONS: Aspart insulin has a listed purchasing cost in Italy equal or higher
than alternatives, but the BIA indicates that its adoption can yield savings for the
hospital, being the hypoglycaemic events management the main cost driver.
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OBJECTIVES: Among patients with type-2 diabetes mellitus (T2DM) previously
treated with only OADs, to evaluate real-world differences in clinical and economic
outcomes following initiating basal analog insulin therapy via disposable pen with
either glargine (GLA-P) or detemir (DET-P). METHODS: The MarketScan databases
(2006–2010) were used to identify patients with T2DM aged 18–79 years and receiv-
ing 1 OAD, but no insulin before initiation of GLA-P or DET-P. Patients had con-
tinuous health plan enrollment for 6 months prior to (baseline) and 1 year after
GLA-P or DET-P initiation (follow-up). Propensity score matching 1:1 was applied to
match the two patient cohorts using baseline demographic and clinical factors.
Study outcomes included treatment persistence and adherence, hypoglycemia-
related medical events, and healthcare utilization and costs during the follow-up.
RESULTS: The 2 matched cohorts (n5771 each, mean age 54, female 49%) were
well balanced for baseline characteristics (all P0.1). During follow-up, patients
initiating GLA-P were more likely to be persistent (42.9 vs. 38.4%, P0.001) and
adherent (adjusted medication possession ratio 0.70 vs. 0.67, P0.001) with treat-
ment versus those initiating DET-P. The average daily study drug consumption
dose was 33U in both cohorts. Fewer GLA-P than DET-P users returned to OAD-only
(18.6 vs. 20.5%, P0.011). Hypoglycemia-related medical events were similar (0.7 vs.
1.0%, P0.093), while the mean number of hypoglycemia-related emergency room
(ER) or hospital events per patient was lower for GLA-P (0.006 vs. 0.012, P0.010).
The diabetes-related pharmacy costs were similar for GLA-P and DET-P ($2,465 vs.
$2513, P0.155), as were the total health care costs ($16,058 vs. $16,209, P0.69).
CONCLUSIONS: Real-world T2DM patients initiating insulin therapy via disposable
pen with GLA-P were more likely to persist and adhere with treatment compared
with patients initiating with DET-P. GLA-P users had fewer ER-/hospital-related
hypoglycemia events, while costs were similar for both.
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OBJECTIVES: The aim of this analysis was to estimate the long-term incremental
clinical and cost outcomes associated with exenatide once weekly (EQW) versus
sitagliptin therapy in type 2 diabetes patients in the UK. Data from DURATION-2; a
phase 3, multinational, randomised, double-blind clinical trial in 491 patients with
type 2 diabetes previously treated with metformin were used. After 26 weeks,
patients receiving EQW (n160) had a significantly greater LS mean HbA1c reduc-
tion (-1.6% versus -0.9%, respectively) and weight reduction (-2.3 kg versus -0.8 kg,
respectively) than patients who received sitagliptin (n166). METHODS: A previ-
ously published and validated diabetes model (IMS CORE Diabetes Model) was used
to make 50 year projections of clinical and cost outcomes based on DURATION-2
baseline patient characteristics and study results. Costs were derived from pub-
lished sources and expressed in 2010 UK Pounds. A discount rate of 3.5 % was
applied to both costs and outcomes. Various sensitivity analyses were performed.
RESULTS: EQW treatment was projected to improve quality-adjusted life expec-
tancy by 0.22 quality-adjusted life years (QALYs) (95% confidence interval 0.12 to
0.32) versus sitagliptin. Total direct medical costs associated with EQW were pro-
jected to be higher over patient lifetimes than with sitagliptin (difference of £1405,
95% confidence interval £444 to £1982), due to higher drug acquisition costs, which
were partially offset by the lower incidence of diabetes-related complications dur-
ing treatment with EQW, and hence cost of treating. The projected incremental
cost effectiveness ratio (ICER) was £6418 per QALY gained. Results of the sensitivity
analysis showed that the ICER was influenced by a reduction in time horizon,
decrease in EQW benefits on HbA1c and increased time on EQW. CONCLUSIONS:
Projected from the DURATION-2 trial, EQW can be considered cost-effective versus
sitagliptin in the UK setting from the NHS perspective. The results were robust to
sensitivity analyses.
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OBJECTIVES: The aim of this analysis was to estimate the cost-effectiveness of
exenatide once weekly (EQW) versus exenatide BID therapy, two formulations of
the same glucagon-like peptide-1 receptor agonist molecule, in type 2 diabetes
patients in the UK. Pooled data from DURATION-1 and DURATION-5, phase 3, ran-
domised, open label clinical trials in 295 and 252 patients respectively, were used.
EQW was associated with greater LS mean HbA1c reduction (-1.7% versus -1.2%,
respectively, p0.001) and weight reduction (-2.9 kg versus -2.4 kg, respectively,
p0.126). METHODS: A previously published and validated diabetes model (IMS
CORE Diabetes Model) was used to make 50 year projections of clinical and cost
outcomes based on pooled DURATION-1 and 5 baseline patient characteristics (age
55.3 years, duration of diabetes 7 years, HbA1c 8.36%) and study results. Costs were
derived from published sources and expressed in 2010 UK Pounds. A discount rate
of 3.5 % was applied to both costs and outcomes. Various sensitivity analyses were
performed. RESULTS: EQW treatment was projected to improve quality-adjusted
life expectancy by 0.18 quality-adjusted life years (QALYs) (95% confidence interval
0.10 to 0.25) and life expectancy by 0.16 years (95% confidence interval 0.07 to 0.26)
versus exenatide BID. EQW was associated with delayed onset of any diabetes-
related complication versus exenatide BID by almost 6 months on average. Due to
the lower incidence of diabetes-related complications during treatment with EQW,
and hence reduction in their treatment costs, EQW was associated with direct
medical cost savings (difference of -£305, 95% confidence interval -£715 to £35).
EQW was therefore projected to be dominant versus exenatide. This result was
robust to all sensitivity analysis. CONCLUSIONS: Based on DURATION-1 and 5,
EQW was projected to be less costly and more effective than exenatide BID over a
patients’ lifetime in the UK setting.
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OBJECTIVES: The World Health Organization has recognized diabetes and other
selected chronic health conditions are at an epidemic level all of which can be
impacted by weight. The purpose of this project was to evaluate the role of diabetes
and Body Mass Index (BMI) on total medical expenses. METHODS: The Medical
Expenditure Panel Survey (MEPS) is publically available database providing nation-
ally representative estimates of health care use, expenditures, sources of payment,
and health insurance coverage for the US population. Analysis of the survey data
utilized design-based methods that utilized the complex survey stratification and
weighting. Regression was utilized to determine the effect of diabetes and BMI
class on total medical expenses in 2008, with inclusion of age, gender, race/ethnic-
ity, and insurance status as additional covariates. Models with and without two-
way interactions were performed. Summary statistics are presented as mean 
standard error. RESULTS: All adults (18 years; n22,128) were included, and av-
erage 2008 medical expenses were estimated at $4493  105. All variables in the
model were significant (p0.001), and adjusting for these factors, patients with
diabetes had an average medical expense of $4,512 410 higher than those without
diabetes. Across both cohorts, the morbid obese (BMI 40) had significantly higher
covariate adjusted medical expenses than normal (18.5 BMI25; $1340  414;
p0.001) and overweight (25 BMI30; $1517  420; p0.001) individuals,
whereas differences with obese (30 BMI40; $784  439; p0.08) and under-
weight (BMI18.5; -$88  754; p0.91) were not significant. CONCLUSIONS: Both
diabetes and high BMI are independently associated with significantly higher med-
ical expenses, and appear to be generally an additive effect. Increase in BMI was
associated with significantly higher medical costs even without diabetes. Morbidly
obese patients with diabetes had annual expenses averaging $12,004.
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OBJECTIVES: To model and evaluate consequences of enhanced treatment of type
2 diabetes mellitus on cost, life expectancy and development of complications in
the Bulgarian health care system. METHODS: The extensively published and vali-
dated CORE Diabetes Model was used to perform lifetime simulations for the rep-
resentative diabetic patient in Bulgaria diagnosed at 55 years. The analysis com-
pared two alternative treatment scenarios with current standards of care. In the
first alternative scenario the model examined the human and economic costs of
10% reduction in the risk factors for developing diabetes related complications. In
the second scenario consequences of treating to targets set in American Diabetes
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